Please login to the form below
Heptares
This page shows the latest Heptares news and features for those working in and with pharma, biotech and healthcare.
GSK signs collaboration deal with Ligand targeting neurological disorders
products. Another deal – signed with Sosei Heptares this week – will see GSK collaborate on the discovery and development of a small molecule target for inflammatory bowel disease and other gastrointestinal immune
Latest news
-
Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance
Targeting largest family of proteins in cell membranes. Sosei Heptares has enticed another big biopharma company to sign up to its G-protein coupled receptor (GPCR) drug discovery platform. ... Sosei Heptares has developed considerable expertise in GPCRs
-
Pfizer’s alliance with Sosei Heptares bears first fruit
The specific targets remain under wraps for now, although Sosei Heptares says they address metabolic and inflammatory diseases. ... The company was officially rebranded Sosei Heptares last December, but is still operating largely independently as a wholly
-
Tox trouble stalls Sosei/Allergan Alzheimer’s drug
The drug is one of the lead candidate from a $3.35bn licensing deal Allergan agreed with Sosei’s Heptares Pharma subsidiary two years ago, covering global rights to a portfolio
-
Pfizer signs high-level deal with GPCR specialist Heptares
biologics drugs - and will pay up to $189m per project to Heptares as well as an undisclosed upfront payment. ... Pfizer's agreement with Heptares is notable because it spans so many targets and indications, according to the UK firm's chief executive
-
Teva buys into Heptares oral CGRP programme for migraine
Signs$410m alliance for early-stage candidates in potentially-lucrative drug class. Teva will co-develop Heptares Pharma's portfolio of migraine therapies in a new alliance valued at up to $410m. ... The agreement - which includes a $10m upfront payment
Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance
Pfizer signs high-level deal with GPCR specialist Heptares
Teva buys into Heptares oral CGRP programme for migraine
More from news
Approximately 3 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Where next in Alzheimer’s disease R&D?
Whereas in the past the sector had “a very singular focus on amyloid”, Sosei Heptares’ chief R&D officer Malcolm Weir said he now thinks it is looking at targets “in ... Other groups, including Sosei Heptares, are working on novel ways to modify
-
30 Women Leaders in UK Healthcare
Dr Fiona Marshall has joined MSD from Heptares Therapeutics, the UK biotech company she co-founded more than a decade ago, which was acquired by Sosei in 2015.
-
Deal Watch March 2017
rights to Heptares’ G protein-coupled receptor product for pain relief. ... 20. Heptares/ Sosei Group. Daiichi Sankyo. Licence. G protein coupled receptor for pain relief.
-
Deal Watch April 2016
Allergan must have known for some time that the Pfizer acquisition was likely to collapse because on the same day as the announcement, Allergan announced a $3.3bn deal with Heptares ... 9, 800. Heptares (JP). Allergan (IE). License and collaboration.
-
Deal Watch November 2015
455. Heptares. Teva. Licence drug-discovery agreement. Small molecule calcitonin gene-related peptide (CGRP) antagonists for migraine. ... 225. Heptares. Pfizer. Strategic discovery collaboration. New therapeutics against up to 10 GPCR targets across
Where next in Alzheimer’s disease R&D?
30 Women Leaders in UK Healthcare
Deal Watch March 2017
More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Metrion Biosciences adds to its board
Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.
-
Sosei appoints chief operating officer
He has served as a non-executive director at Sosei since 2010, and has since worked at Syngene International, where he was chief executive and executive director, and Heptares Therapeutics, where
-
Former Amgen EVP Roger Perlmutter joins Heptares board
Also has experience at Merck &Co. Heptares has appointed Amgen's former executive VP, R&D, Dr Roger Perlmutter, to its board of directors. ... Dr Perlmutter said: “Heptares has pioneered structure determination in GPCRs, and has used this information
Metrion Biosciences adds to its board
Sosei appoints chief operating officer
Former Amgen EVP Roger Perlmutter joins Heptares board
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Senior Medical Writer
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Associate Account Director
-
Competitive Salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
-
Publications Director
-
Competitive Salary
-
Senior Account Executive
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
-
Account Management
-
Competitive Salary Offered
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Account Manager
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
Medical Editor
-
Competitive Salary
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
